{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:47Z","timestamp":1787021087560,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The standard of care in recurrent\/metastatic head and neck squamous cell carcinoma is Pembrolizumab with\/without chemotherapy. However, these regimens are minimally affordable and accessible in resource-limited countries. Hence, immunotherapy is combined with oral metronomic chemotherapy in lower doses. Currently, the efficacy and safety of this regimen have been studied in platinum-refractory settings and not beyond them. Thus, we conducted a real-world study on the effectiveness of low-dose immunotherapy and metronomic chemotherapy in recurrent\/metastatic head and neck cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>This was a multicentre, real-world, prospective observational study. Recurrent\/metastatic head and neck squamous cell carcinoma patients treated with palliative intent with an Eastern Cooperative Oncology Group performance status of 0\u20132 were recruited from three oncology centres. Patients received oral metronomic chemotherapy with IV nivolumab 20\u00a0mg once every 3 weeks. Patients received treatment until disease progression or unacceptable toxicities. The primary endpoints were Objective response rate, progression-free survival, and Overall survival. The secondary endpoint was safety. Moreover, subgroup analysis was also carried out among platinum sensitivity and the line of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 123 patients were recruited (86% males and 35% females). The Objective response rate was 61.7% (95% CI, 53 to 70). The median overall survival and progression-free survival were 15.1 months (95% CI, 12.8\u201317.4) and 10.4 months (95% CI, 8.0-13.7), respectively. Moreover, the median overall survival was 15.9 (95% CI, 12.7 to 17.5) versus 8.0 months (95% CI, 3.4\u201312.6) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and the median progression-free survival were 13.6 months (95% CI, 9.9\u201317.2) versus 5.0 months (95% CI, 2.2\u20137.8) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) for platinum sensitive and resistant subgroups respectively. The median OS were 15.1 months (95% CI, 12.7\u201317.5) versus 8.0 months (3.4\u201312.6) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and the median PFS were 11.2 months (95% CI, 6.3\u201316.0) versus 6.0 months (95% CI, 2.7\u20139.3) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07) for first and second-line subgroups, respectively. The most common adverse events were fatigue (63.4%), anemia (52.8%), mucositis (47.9%), and rashes (44.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that adding low-dose immunotherapy to oral metronomic chemotherapy was effectively applicable and associated with manageable toxicities in a real-world setting for the management of R\/M HNSCC. Furthermore, this regimen was associated with favourable survival outcomes and response rates in the platinum-sensitive and first-line treatment subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00356-9","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:03:26Z","timestamp":1780268606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A real-world study of the effectiveness and safety of low-dose immunotherapy in addition to oral metronomic chemotherapy in recurrent and metastatic head and neck squamous cell carcinoma"],"prefix":"10.1186","volume":"38","author":[{"given":"Rushabh","family":"Kothari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Khadela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurang","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itesh","family":"Khatwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vraj B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"356_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"key":"356_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","volume":"29","author":"M Tahara","year":"2018","unstructured":"Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;29:1004\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy040.","journal-title":"Ann Oncol"},{"key":"356_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"356_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508\/SUPPL_FILE\/PROTOCOL_JCO.21.02508.PDF","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Souli\u00e8res D, Tahara M, De Castro G, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023;41:790\u2013802. https:\/\/doi.org\/10.1200\/JCO.21.02508\/SUPPL_FILE\/PROTOCOL_JCO.21.02508.PDF.","journal-title":"J Clin Oncol"},{"key":"356_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.clon.2021.01.004","volume":"33","author":"VM Patil","year":"2021","unstructured":"Patil VM, Abraham G, Noronha V, Joshi A, Menon N, Singh GK, et al. The Pattern of Care of Use of Nivolumab in Head and Neck Cancers \u2013 Audit From a Tertiary Cancer Centre. Clin Oncol. 2021;33:342. https:\/\/doi.org\/10.1016\/j.clon.2021.01.004.","journal-title":"Clin Oncol"},{"key":"356_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMOA0802656\/ASSET\/A666E058-0210-4F26-B697-A012FB7B4135\/ASSETS","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359:1116\u201327. https:\/\/doi.org\/10.1056\/NEJMOA0802656\/ASSET\/A666E058-0210-4F26-B697-A012FB7B4135\/ASSETS\/IMAGES\/LARGE\/NEJMOA0802656_T3.JPG.","journal-title":"N Engl J Med"},{"key":"356_CR7","doi-asserted-by":"publisher","first-page":"217702","DOI":"10.1016\/J.CANLET.2025.217702","volume":"621","author":"R Kothari","year":"2025","unstructured":"Kothari R, Patil V, Madala R, krishna, Singh R, Talreja VT, Pathak A, et al. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes. Cancer Lett. 2025;621:217702. https:\/\/doi.org\/10.1016\/J.CANLET.2025.217702.","journal-title":"Cancer Lett"},{"key":"356_CR8","doi-asserted-by":"publisher","first-page":"e1213","DOI":"10.1016\/S2214-109X(20)30275-8","volume":"8","author":"V Patil","year":"2020","unstructured":"Patil V, Noronha V, Dhumal SB, Joshi A, Menon N, Bhattacharjee A, et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health. 2020;8:e1213\u201322. https:\/\/doi.org\/10.1016\/S2214-109X(20)30275-8.","journal-title":"Lancet Glob Health"},{"key":"356_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMOA1602252\/SUPPL_FILE","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMOA1602252\/SUPPL_FILE\/NEJMOA1602252_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"key":"356_CR10","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609.","journal-title":"J Clin Oncol"},{"key":"356_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015\/SUPPL_FILE\/PROTOCOL_JCO.22.01015.PDF","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol. 2023;41:222\u201332. https:\/\/doi.org\/10.1200\/JCO.22.01015\/SUPPL_FILE\/PROTOCOL_JCO.22.01015.PDF.","journal-title":"J Clin Oncol"},{"key":"356_CR12","doi-asserted-by":"publisher","unstructured":"Khadela A, Shah Y, Mistry P, Bodiwala K. Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects n.d. https:\/\/doi.org\/10.1177\/15330338221150559.","DOI":"10.1177\/15330338221150559"},{"key":"356_CR13","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.19.01076\/SUPPL_FILE\/DS_JCO.19.01076.PDF","volume":"37","author":"VM Patil","year":"2019","unstructured":"Patil VM, Noronha V, Joshi A, Dhumal S, Mahimkar M, Bhattacharjee A, et al. Phase I\/II study of palliative triple metronomic chemotherapy in platinum-refractory\/ early-failure oral cancer. J Clin Oncol. 2019;37:3032\u201341. https:\/\/doi.org\/10.1200\/JCO.19.01076\/SUPPL_FILE\/DS_JCO.19.01076.PDF.","journal-title":"J Clin Oncol"},{"key":"356_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/S40267-020-00732-Y\/METRICS","volume":"36","author":"A Khadela","year":"2020","unstructured":"Khadela A, Vyas B. Assessment of the utilization pattern of chemotherapy agents in patients with head and neck cancer in an oncology hospital. Drugs Therapy Perspect. 2020;36:303\u20139. https:\/\/doi.org\/10.1007\/S40267-020-00732-Y\/METRICS.","journal-title":"Drugs Therapy Perspect"},{"key":"356_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015;ISSUE:ISSUE:DOI","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol. 2023;41:222\u201332. https:\/\/doi.org\/10.1200\/JCO.22.01015;ISSUE:ISSUE:DOI.","journal-title":"J Clin Oncol"},{"key":"356_CR16","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.22.02398","volume":"41","author":"DC Mo","year":"2023","unstructured":"Mo DC, Huang JF, Luo PH. Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer. J Clin Oncol. 2023;41:1790. https:\/\/doi.org\/10.1200\/JCO.22.02398.","journal-title":"J Clin Oncol"},{"key":"356_CR17","doi-asserted-by":"publisher","first-page":"S1567","DOI":"10.1016\/J.ANNONC.2024.10.463","volume":"35","author":"SK Swain","year":"2024","unstructured":"Swain SK, Moharana L, Dubey A, Singhal R, Sanyal A, Biswas G, et al. 440P Low-dose nivolumab six weekly plus triple metronomic chemotherapy in advanced head and neck cancer: A prospective, open label single centre study from eastern India. Ann Oncol. 2024;35:S1567. https:\/\/doi.org\/10.1016\/J.ANNONC.2024.10.463.","journal-title":"Ann Oncol"},{"key":"356_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/HED.70077","volume":"48","author":"A Khadela","year":"2026","unstructured":"Khadela A, Parikh R, Vaghela J, Chauhan Y, Shah VB, Kothari R, et al. A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients. Head Neck. 2026;48:765\u201373. https:\/\/doi.org\/10.1002\/HED.70077.","journal-title":"Head Neck"},{"key":"356_CR19","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/S41598-022-06084-Z","volume":"12","author":"I Okamoto","year":"2022","unstructured":"Okamoto I, Tsukahara K, Sato H. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. Sci Rep. 2022;12:2025. https:\/\/doi.org\/10.1038\/S41598-022-06084-Z.","journal-title":"Sci Rep"},{"key":"356_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/00016489.2018.1551623","volume":"139","author":"H Sato","year":"2019","unstructured":"Sato H, Tsukahara K, Okamoto I, Katsube Y, Shimizu A, Kondo T, et al. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. Acta Otolaryngol. 2019;139:201\u20135. https:\/\/doi.org\/10.1080\/00016489.2018.1551623.","journal-title":"Acta Otolaryngol"},{"key":"356_CR21","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.21873\/ANTICANRES.13898","volume":"39","author":"D Sano","year":"2019","unstructured":"Sano D, Fujisawa T, Tokuhisa M, Shimizu M, Sakagami T, Hatano T, et al. Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan. Anticancer Res. 2019;39:6819\u201327. https:\/\/doi.org\/10.21873\/ANTICANRES.13898.","journal-title":"Anticancer Res"},{"key":"356_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/CANCERS11091317","volume":"11","author":"R Hori","year":"2019","unstructured":"Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I, et al. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers (Basel). 2019;11:1317. https:\/\/doi.org\/10.3390\/CANCERS11091317.","journal-title":"Cancers (Basel)"},{"key":"356_CR23","doi-asserted-by":"publisher","first-page":"105093","DOI":"10.1016\/J.ORALONCOLOGY.2020.105093","volume":"112","author":"AL Mazul","year":"2021","unstructured":"Mazul AL, Naik AN, Zhan KY, Stepan KO, Old MO, Kang SY, et al. Gender and race interact to influence survival disparities in head and neck cancer. Oral Oncol. 2021;112:105093. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2020.105093.","journal-title":"Oral Oncol"},{"key":"356_CR24","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/J.OOR.2023.100141","volume":"9","author":"B Ram","year":"2024","unstructured":"Ram B, Rao SLCS, Fonseca D, Ch SK, Gondi J, Akula AK, et al. Worst pattern of invasion: A prognostic indicator in early-stage oral tongue cancer: A single-center cohort study. Oral Oncol Rep. 2024;9:100141. https:\/\/doi.org\/10.1016\/J.OOR.2023.100141.","journal-title":"Oral Oncol Rep"},{"key":"356_CR25","doi-asserted-by":"publisher","first-page":"106808","DOI":"10.1016\/J.ORALONCOLOGY.2024.106808","volume":"154","author":"P Liokatis","year":"2024","unstructured":"Liokatis P, Liokati I, Obermeier K, Smolka W, Ersan F, Dewenter I, et al. Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review. Oral Oncol. 2024;154:106808. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2024.106808.","journal-title":"Oral Oncol"},{"key":"356_CR26","doi-asserted-by":"publisher","first-page":"102361","DOI":"10.1016\/J.ESMOOP.2024.102361","volume":"9","author":"AD Khadela","year":"2024","unstructured":"Khadela AD, Merja MR. 33P A phase IV study of EXTREME regimen versus nivolumab plus paclitaxel and cisplatin\/carboplatin-based regimen in recurrent or metastatic squamous cell carcinoma of the head and neck. ESMO Open. 2024;9:102361. https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.102361.","journal-title":"ESMO Open"},{"key":"356_CR27","doi-asserted-by":"publisher","unstructured":"Barham WT, Stagg MP, Mualla R, DiLeo M, Kansara S. Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/CANCERS17010144.","DOI":"10.3390\/CANCERS17010144"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00356-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:33Z","timestamp":1781650533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00356-9","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethics standards of the 1964 Declaration of Helsinki. The Ethics Committee of L.M. College of Pharmacy approved the study and granted permission to conduct it. All patients provided written informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}